Analytical performance evaluation of the Cobas 6000 analyzer – special emphasis on trueness verification
-
Adriaan J. van Gammeren
Abstract
Background: Consolidation of analyzers is an emerging issue in clinical chemistry. We evaluated the analytical performance of the Cobas 6000 analyzer (Roche Diagnostics), which is considered a candidate for replacement of current Hitachi 917 analyzers and for consolidation of chemistry and immunochemistry.
Methods: The precision, accuracy, linearity and correlation with current field methods were evaluated according to Clinical and Laboratory Standards Institute protocols EP5, EP9 and EP10. A total of 31 routine chemistry assays and 18 immunoassays were studied. Accuracy and linearity were verified for 24 chemistry parameters using value-assigned trueness controls from the Dutch External Quality Assessment Scheme organizers. In addition, traceability to methods endorsed by the Joint Committee of Traceability in Laboratory Medicine was examined.
Results: All analytes met allowable precision criteria, apart from the low level for sodium and folate. Total coefficients of variation ranged between 0.6% and 4.4% for routine chemistry and between 0.8% and 5.8% for immunochemistry, apart from folate (12% at the low end). The correlation coefficients for comparison to current field methods were >0.975, except for magnesium and for six out of 18 immunochemistries. Recovery experiments indicated high recovery for most of the 24 routine chemistry assays.
Conclusions: Considering the excellent precision data and the result equivalence for most assays, it can be concluded that Cobas 6000 accommodates robust chemistry and immunochemistry, and has good potential for workstation consolidation in medium-sized laboratories.
Clin Chem Lab Med 2008;46:863–71.
©2008 by Walter de Gruyter Berlin New York
Articles in the same Issue
- Reviews
- The STANISLAS Cohort: a 10-year follow-up of supposed healthy families. Gene-environment interactions, reference values and evaluation of biomarkers in prevention of cardiovascular diseases
- Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiology practice
- Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories
- Cardiovascular Diseases
- APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels
- Gender-modulated impact of apolipoprotein A5 gene (APOA5) −1131T>C and c.56C>G polymorphisms on lipids, dyslipidemia and metabolic syndrome in Turkish adults
- Oxidative stress markers, C-reactive protein and heat shock protein 70 levels in subjects with metabolic syndrome
- Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing
- Distribution of plasma cardiac troponin I values in healthy subjects: pathophysiological considerations
- High-density lipoprotein cholesterol and paraoxonase 1 (PON1) genetics and serum PON1 activity in prepubertal children in Spain
- Genetics and Molecular Diagnostics
- Polymorphisms of CYP17A1, CYP19, and androgen in Brazilian women with uterine leiomyomas
- A novel MEN1 frameshift germline mutation in two Italian monozygotic twins
- The silent hemoglobin α chain variant Hb Riccarton [α51(CE9)Gly→Ser] may affect HbA1c determination on the HLC-723 G7 analyzer
- General Clinical Chemistry and Laboratory Medicine
- Urinary fructose-1,6-bisphosphatase activity as a marker of the damage to the renal proximal tubules in children with idiopathic nephrotic syndrome
- Antioxidant defense capacity in scleroderma patients
- Correction of ventricular cerebrospinal fluid (CSF) samples for blood content does not increase sensitivity and specificity for the detection of CSF infection
- Validation and Outcome Studies
- Preanalytical quality control program – an overview of results (2001–2005 summary)
- A laboratory-based risk score for medical intensive care patients
- Analytical performance evaluation of the Cobas 6000 analyzer – special emphasis on trueness verification
- Letters to the Editor
- Quality planning and analytical quality requirements derived from biology
- Importance of sample size in hospital point-of-care glucose measurements
- Reliability of M protein quantification: comparison of two peak integration methods on Capillarys 2
- What's in a name? Standardization of HbA1c
- Serum paraoxonase 1 activities and homocysteinemia in hemodialysis patients
Articles in the same Issue
- Reviews
- The STANISLAS Cohort: a 10-year follow-up of supposed healthy families. Gene-environment interactions, reference values and evaluation of biomarkers in prevention of cardiovascular diseases
- Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiology practice
- Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories
- Cardiovascular Diseases
- APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels
- Gender-modulated impact of apolipoprotein A5 gene (APOA5) −1131T>C and c.56C>G polymorphisms on lipids, dyslipidemia and metabolic syndrome in Turkish adults
- Oxidative stress markers, C-reactive protein and heat shock protein 70 levels in subjects with metabolic syndrome
- Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing
- Distribution of plasma cardiac troponin I values in healthy subjects: pathophysiological considerations
- High-density lipoprotein cholesterol and paraoxonase 1 (PON1) genetics and serum PON1 activity in prepubertal children in Spain
- Genetics and Molecular Diagnostics
- Polymorphisms of CYP17A1, CYP19, and androgen in Brazilian women with uterine leiomyomas
- A novel MEN1 frameshift germline mutation in two Italian monozygotic twins
- The silent hemoglobin α chain variant Hb Riccarton [α51(CE9)Gly→Ser] may affect HbA1c determination on the HLC-723 G7 analyzer
- General Clinical Chemistry and Laboratory Medicine
- Urinary fructose-1,6-bisphosphatase activity as a marker of the damage to the renal proximal tubules in children with idiopathic nephrotic syndrome
- Antioxidant defense capacity in scleroderma patients
- Correction of ventricular cerebrospinal fluid (CSF) samples for blood content does not increase sensitivity and specificity for the detection of CSF infection
- Validation and Outcome Studies
- Preanalytical quality control program – an overview of results (2001–2005 summary)
- A laboratory-based risk score for medical intensive care patients
- Analytical performance evaluation of the Cobas 6000 analyzer – special emphasis on trueness verification
- Letters to the Editor
- Quality planning and analytical quality requirements derived from biology
- Importance of sample size in hospital point-of-care glucose measurements
- Reliability of M protein quantification: comparison of two peak integration methods on Capillarys 2
- What's in a name? Standardization of HbA1c
- Serum paraoxonase 1 activities and homocysteinemia in hemodialysis patients
